Format

Send to

Choose Destination
Haematologica. 2018 Nov;103(11):1756-1757. doi: 10.3324/haematol.2018.201897.

To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia.

Author information

1
Vaccine and Infectious Diseases and Clinical Research Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA.
2
Department of Medicine, University of Washington, Seattle, WA.
3
Department of Oncology Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI, USA schiffer@karmanos.org.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center